- Home
- TNYA vs OVID Comparison
TNYA vs OVID Comparison
Compare TNYA & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNYA | OVID |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 117.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TNYA | OVID |
|---|---|---|
| Price | $0.56 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $5.25 | $3.40 |
| AVG Volume (30 Days) | ★ 3.6M | 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.02 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $566,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.24 |
| 52 Week High | $2.35 | $2.01 |
Technical Indicators
Market Signals| Indicator | TNYA | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 56.32 |
| Support Level | $0.39 | $1.43 |
| Resistance Level | $0.72 | $1.70 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.10 | 86.76 |
Price Performance
Historical ComparisonAbout TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.